Quick medicine delivery startup Plazza has raised $15 million in a Series A funding round co-led by Accel, Elevation Capital, and Nexus Venture Partners. Existing investors All In Capital and Better Capital also participated in the round.
The startup will use the fresh capital to expand its store network across India, founder and chief executive Aman Priyadarshi said on Monday.
“We have a couple of stores in Bengaluru that we have been experimenting with, and now we’ve raised capital to increase our geographical footprint. We are launching about 10 stores very quickly in the next eight weeks, and we will have about 20 stores in the city by the end of this year,” he said.
Furthermore, Plazza plans to enter additional cities over the next year and aims to establish more than 3,000 stores across the country within the next three to four years.
Founded in 2024, Plazza differentiates itself by maintaining a significantly larger medicine inventory while offering deliveries within 15 to 30 minutes, allowing it to compete in India’s increasingly competitive pharmacy market.
Unlike traditional pharmacies, which primarily serve walk-in customers within smaller catchment areas, and online pharmacy platforms that prioritize inventory over delivery speed, Plazza focuses on serving a wider delivery radius while ensuring rapid order fulfillment.
Additionally, the startup leverages artificial intelligence to create store-specific inventories based on demand patterns across individual micro-markets.
The newly raised capital will also help strengthen Plazza’s technology platform by further enhancing its AI-powered inventory planning and assortment intelligence capabilities.
Plazza operates an omnichannel model that combines physical pharmacy stores with online ordering, although the company primarily focuses on digital transactions.
“We expect our customers to place an order on an app or WhatsApp, and we deliver. We use a large part of the space to store inventory, and that’s how we have done our manpower planning, our store design, etc.,” said Priyadarshi.
Unlike conventional retail pharmacies that typically stock around 5,000 medicines, resulting in prescription fill rates of 50–60%, Plazza maintains an inventory of more than 40,000 stock-keeping units (SKUs). Moreover, its AI-powered inventory system continuously learns neighbourhood prescribing patterns to optimize medicine availability.
According to the company, only about 50% of the top-selling medicines overlap between its two Bengaluru stores, highlighting significant differences in prescription demand across nearby micro-markets.
Plazza also reported substantial business growth, with its gross merchandise value (GMV) increasing approximately 27 times between June 2025 and March 2026.
India’s organized pharmacy retail market has witnessed rapid consolidation, with major players such as Tata 1mg and Apollo 24/7 dominating the sector. Meanwhile, recent funding activity has largely focused on startups addressing specific market gaps. In August 2025, generics-focused Truemeds raised $85 million in a Series C round led by Accel and Peak XV Partners, while PlatinumRx secured $6 million in a Series A round led by Stellaris Venture Partners in September 2025.
